On Friday, H.C. Wainwright reaffirmed its Buy rating and $25.00 price target on shares of Innate Pharma (EPA:IPH) S.A. (NASDAQ:IPHA), currently trading at $1.67, following the company's ...

IPH provides intellectual property services through its seven subsidiaries, covering patent filing, prosecution, enforcement, management, design, trademarks, and more. Its diverse client base ...

In a report released today, Sam Haddad from Petra Capital maintained a Buy rating on IPH Ltd. (IPH – Research Report), with a price target of A$8.00. The company’s shares opened today at A$4.57.

ASX company news and announcements for IPH Limited (IPH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All IPH Limited (IPH) ASX ...